Strategic partnerships Recent collaboration activity with major pharma players (Sanofi, Bristol Myers Squibb, Lilly) indicates a strong openness to co-development and licensing. This suggests sales opportunities in partnering for antibody discovery, immunogenicity, and vaccine screening using Prellis EXIS platform.

Therapeutic focus Active pursuit of human antibody therapeutics for selected targets signals a fit for externalized immune system capabilities. Targeted outreach to biopharma and biotech firms pursuing antibody programs could yield co-development or sponsored research deals.

Technology leverage High-resolution bioprinting and EXIS platform capabilities align with needs of companies requiring rapid antibody discovery and immunogenicity screening. Position Prellis as a platform enabler to accelerate preclinical programs and reduce timelines.

Funding momentum Significant Series C funding and new leadership point to validated growth and scalability. This creates opportunities to approach portfolio expansion, licensing conversations, or joint ventures with investors and strategic partners seeking to de-risk early-stage programs.

Market readiness Comparable peers show strong demand in biotherapeutics and organ/tissue engineering. Emphasize EXIS’s integrated workflow as a differentiator for antibody discovery and vaccine screening in collaborative research agreements or sponsored programs.